Brief: Prometheus Biosciences Reports Q4 And FY 2022 Financial Results And Highlights Recent Corporate Progress

Prometheus Biosciences

28/02/2023 22:07

Feb 28 (Reuters) - Prometheus Biosciences Inc  RXDX.O :
    * PROMETHEUS BIOSCIENCES REPORTS FOURTH QUARTER AND
FULL-YEAR 2022
FINANCIAL RESULTS AND HIGHLIGHTS RECENT CORPORATE PROGRESS
    * INTENDS TO ADVANCE PRA023 INTO PHASE 3 STUDIES FOR UC AND
CD IN
2023
    * INITIATED A THIRD PHASE 2 OF PRA023 INTO SSC-ILD,
DEMONSTRATING
PIPELINE-IN-A-PRODUCT CANDIDATE POTENTIAL FOR PROGRAM
    * AS OF DECEMBER 31, 2022, PROMETHEUS HAD CASH, CASH
EQUIVALENTS
AND SHORT-TERM INVESTMENTS OF $695.8 MILLION
    * REPORTED STRONG EFFICACY AND FAVORABLE SAFETY RESULTS FOR
PRA023
IN ARTEMIS-UC AND APOLLO-CD PHASE 2 STUDIES
    * QTRLY LOSS PER SHARE $0.90
    * Q4 EARNINGS PER SHARE VIEW $-0.92 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX1VtTgH 
Further company coverage:  RXDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))